Prime Medicine (PRME) Operating Leases (2021 - 2025)
Prime Medicine (PRME) has disclosed Operating Leases for 5 consecutive years, with $110.4 million as the latest value for Q3 2025.
- For the quarter ending Q3 2025, Operating Leases rose 200.35% year-over-year to $110.4 million, compared with a TTM value of $110.4 million through Sep 2025, up 200.35%, and an annual FY2024 reading of $37.2 million, up 753.34% over the prior year.
- Operating Leases was $110.4 million for Q3 2025 at Prime Medicine, down from $112.5 million in the prior quarter.
- Across five years, Operating Leases topped out at $112.5 million in Q2 2025 and bottomed at $3.1 million in Q4 2021.
- Average Operating Leases over 5 years is $37.9 million, with a median of $32.5 million recorded in 2022.
- The sharpest move saw Operating Leases crashed 81.48% in 2023, then soared 753.34% in 2024.
- Year by year, Operating Leases stood at $3.1 million in 2021, then skyrocketed by 455.41% to $17.1 million in 2022, then crashed by 74.45% to $4.4 million in 2023, then skyrocketed by 753.34% to $37.2 million in 2024, then soared by 196.99% to $110.4 million in 2025.
- Business Quant data shows Operating Leases for PRME at $110.4 million in Q3 2025, $112.5 million in Q2 2025, and $78.6 million in Q1 2025.